Gan & Lee Pharmaceuticals.

603087

CNE100003ZH1

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 11/06/2026			5-day change	1st Jan Change
55.81 ^CNY	-0.59%		+3.91%	-18.01%

05-15	Sandoz Group AG Confirms European Commission Approval for Biosimilars Bysumlog® (Insulin Lispro) and Dazparda® (Insulin Aspart), Strengthening Position in Diabetes	CI
05-07	Gan & Lee Pharmaceuticals Gets Nod to Market Dazparda in Europe	MT

Gan & Lee Pharmaceuticals. Reports Earnings Results for the First Quarter Ended March 31, 2026

Published on 04/22/2026 at 11:27 am BST

S&P Capital IQ

GAN & LEE PHARMACEUTICALS.

-0.59%

Gan & Lee Pharmaceuticals. reported earnings results for the first quarter ended March 31, 2026. For the first quarter, the company reported sales was CNY 878.11 million compared to CNY 984.87 million a year ago.

Revenue was CNY 878.11 million compared to CNY 984.87 million a year ago. Net income was CNY 192.49 million compared to CNY 311.92 million a year ago. Basic earnings per share from continuing operations was CNY 0.33 compared to CNY 0.53 a year ago.

Diluted earnings per share from continuing operations was CNY 0.33 compared to CNY 0.53 a year ago.

Latest news about Gan & Lee Pharmaceuticals.

05-15	Sandoz Group AG Confirms European Commission Approval for Biosimilars Bysumlog® (Insulin Lispro) and Dazparda® (Insulin Aspart), Strengthening Position in Diabetes	CI
05-07	Gan & Lee Pharmaceuticals Gets Nod to Market Dazparda in Europe	MT
04-22	Gan & Lee Pharmaceuticals 2025 net profit up 86.1% y/y	RE
04-22	Gan & Lee Pharmaceuticals. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-21	Gan & Lee Pharmaceuticals. announces Annual dividend, payable on May 29, 2026	CI
04-16	Gan & Lee Pharmaceuticals Gets Nod to Trial GLR1062 Injection	MT
04-15	Gan & Lee Pharmaceuticals' Subsidiary Doses First Subject for Phase III of GZR33 Injection Trial; Shares Up 3%	MT
04-09	Gan & Lee Pharmaceuticals - signs exclusive license agreement with JW Pharmaceutical	RE
04-09	Gan & Lee Pharmaceuticals and Jw Pharmaceutical Sign Exclusive License Agreement for Bofanglutide Injection in South Korea	CI
04-08	Gan & Lee Pharmaceuticals Gets Regulatory Approval for Diabetes Combo Drug	MT
04-07	Gan & Lee Pharmaceuticals Doses First Patient in Prostate Cancer Drug Trial	MT
03-31	Gan & Lee Pharmaceuticals Announces Once-Weekly Basal Insulin GZR4 Injection Meets Primary Endpoints In Two Pivotal Phase 3 Clinical Trials	CI
03-25	Gan & Lee Pharmaceuticals Gets Drug Trial Approval to Treat Obesity-Related Sleep Apnea	MT
03-03	Gan & Lee Pharmaceuticals Gets Regulatory Nod for Prostate Cancer Drug Trials	MT
01-22	Gan & Lee Pharmaceuticals Expects 2025 Profit to Jump Up to 95%	MT

Chart Gan & Lee Pharmaceuticals.

Duration

Period

603087: Dynamic Chart

Company Profile

Gan & Lee Pharmaceuticals is a China-based company primarily engaged in the research, development, production, and sales of insulin analogue active pharmaceutical ingredients and injectable formulations. The Companyâ€™s main products include glargine insulin injection, lispro insulin injection, mixed protamine zinc lispro insulin injection, aspart insulin injection, aspart 30 insulin injection, and mixed protamine human insulin injection. The Company is also engaged in the provision of medical device products, including reusable pen insulin injectors, non-reusable pen injectors, disposable injection pen needles, and disposable insulin pen needles. The Company distributes its products within the domestic market and to overseas markets.

Employees

5,309

Sector

Pharmaceuticals

More about the company